Triple Recipient Strategy Using Split,… | Clinical Trial

Key information

Conditions

Hepatocellular Carcinoma (HCC) Adenocarcinoma Amino Acid Metabolism, Inborn Errors Brain Diseases Brain Diseases, Metabolic Brain Diseases, Metabolic, Inborn Carcinoma Carcinoma, Hepatocellular Central Nervous System Diseases Congenital, Hereditary, and Neonatal Diseases and Abnormalities Digestive System Diseases Digestive System Neoplasms Fibrosis Genetic Diseases, Inborn Hyperargininemia Liver Diseases Liver Neoplasms Metabolic Diseases Metabolism, Inborn Errors Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Nervous System Diseases Nutritional and Metabolic Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Urea Cycle Disorders, Inborn

Sex eligibility

All sexes

Study type

Observational

Primary location

2ndAffiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, 310009, China

About this study

The investigators report a case of the simultaneous use of split liver transplantation (SLT), domino liver transplantation (DLT) and auxiliary liver transplantation (ALT) to achieve "one donor for three recipients". Three recipients had hepatitis C cirrhosis, argininemia, and hepatocellular carcinoma (HCC), respectively. The investigators performed SLT in the first two recipients (an adult and a child), with the donor liver coming from a female who died of severe head trauma. The right lobe of the child, as the "domino liver graft", was transplanted to the postoperative HCC patient, whose left lateral lobe was preserved after tumor resection. All recipients were discharged from the hospital. During the 12 months of follow-up, all three recipients remained alive.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

liver cirrhosis
argininemia
hepatocellular carcinoma

Exclusion criteria

Patients who do not require an allogeneic liver transplantation.

Treatment and study plan

Primary outcomes

Postoperative survival time

Time frame: 2023/04-2024/04

The duration of time a patient survives after undergoing a surgical procedure.

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Other

Registry information

Official study title

Expanding Donor Liver Utilization: a Case Series Study of Triple Recipient Strategy Using Split, Domino, and Auxiliary Techniques.

Important dates

Study start: 2023
Primary completion: 2024
Study completion: 2024
First posted: Nov 12, 2024
Registry last updated: Dec 5, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting